首页> 外文OA文献 >29. Rapid Restoration of Bile Acid Compositions After Treatment with Investigational Microbiota-based Therapeutic RBX2660 for Recurrent clostrioides Difficile Infection

【2h】

29. Rapid Restoration of Bile Acid Compositions After Treatment with Investigational Microbiota-based Therapeutic RBX2660 for Recurrent clostrioides Difficile Infection

机译：29.用基于研究微生物群的治疗RBX2660治疗胆酸组合物的快速恢复胆汁酸组合物用于复发性梭菌差异感染

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Nicky Ferdyan; Romeo Papazyan; Dana Walsh; Sarah Klein; Steve Qi; Ken Blount; Karthik Srinivasan; Bryan Fuchs;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of RBX2660: An Investigational Microbiome Restoration Therapeutic [J] . Ken F Blount, William D Shannon, Elena Deych, Open Forum Infectious Diseases . 2019,第4期

机译：RBX2660的2期试验中细菌微生物组组成的恢复和治疗应答者之间的多样性：一种研究性微生物组恢复疗法
2. Quality of Life Increased After Treatment for Participants in a Phase 2B Randomized, Double-Blinded, Placebo-Controlled Clinical Trial of RBX2660 for Preventing Recurrent Clostridium difficile Infections [J] . Guthmueller Beth, Orenstein Robert, Dubberke Erik, The American Journal of Gastroenterology . 2018,第Suppla2期

机译：治疗参与者的生活质量增加了A期2B的随机，双盲，安慰剂对照临床试验，用于预防复发性梭菌感染的RBX2660
3. Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection [J] . Seekatz Anna M., Theriot Casey M., Rao Krishna, Anaerobe . 2018,第期

机译：复发性梭菌感染患者粪便微生物A移植后粪便微生物酸盐癌患者恢复短链脂肪酸和胆汁酸代谢
4. Association of Stool Bile Acid Profiles with Clostridioides Difficile Infection Treatment Regimens and Related Changes in the Gut Microbiota [D] . ?Qian, Xi 2020

机译：用梭菌偶氮偶胆梭菌感染治疗方案的粪便胆汁酸谱和肠道微生物瘤中的相关变化
5. LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy Durability and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections [O] . Robert Orenstein, Sarah Mische, Sarah Mische, -1

机译：LB5。一个长期的未来：最终的为期2年的功效耐久性和微生物组变化的研究基于微生物菌的药物RBX2660用于复发性艰难梭菌感染的对照开放标签试验。
6. 624 – Comparison of Two Open-Label Trials Demonstrates Similar 6-Month Outcomes for Rbx2660 and Rbx7455—Investigational Microbiota Restoration Therapeutics Administered by Enema Or Oral Capsules for Preventing Recurrent Clostridium Difficile Infections [O] . Ken Blount, Dale N. Gerding, Sahil Khanna, 2019

机译：624 - 两项开放标签试验的比较表明RBX2660和RBX7455-Investigational Microbiota恢复治疗剂的相似6个月的结果用于预防复发性梭菌感染的灌肠或口腔胶囊

29. Rapid Restoration of Bile Acid Compositions After Treatment with Investigational Microbiota-based Therapeutic RBX2660 for Recurrent clostrioides Difficile Infection

著录项

引文网络

相似文献

相关主题

期刊订阅